New triple therapy offers hope for advanced nose cancer patients

NCT ID NCT07325539

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 20 times

Summary

This study tests whether adding low-dose radiation to a standard chemotherapy plus immunotherapy combination can help control advanced nasopharyngeal cancer that has returned or spread. About 55 adults aged 18-65 with this specific cancer type will receive the treatment. The goal is to see if the combination improves how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Shenzhen, Guangdong, 518116, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NASOPHARANGEAL CANCER NASOPHARYNGEAL CANCINOMA (NPC)